David Cohen, MD
Urology · Seaford, DENPI 1922191568
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,408 of the $3,808 with a category attached, or 63.3%. Procept Biorobotics Corporation accounts for 65.4% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $1,441, 2.2 times the $658 reported in 2019.
Across 62 payments — averaging $61.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$2K
- Boston Scientific$390
- Astellas Pharma US Inc$184
- Sumitomo Pharma America, Inc.$167
- Myriad Women's Health, Inc.$89
- Ferring Pharmaceuticals Inc.$76
- plus $412 from 12 others
What the payments were for
- Travel & lodging$2,40863%
- Food & beverage$1,39937%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 12 | $2,490 |
| Boston Scientific | 4 | $390 |
| Astellas Pharma US Inc | 13 | $184 |
| Sumitomo Pharma America, Inc. | 8 | $167 |
| Myriad Women's Health, Inc. | 1 | $89 |
| Ferring Pharmaceuticals Inc. | 4 | $76 |
| AbbVie | 3 | $70 |
| Pfizer | 4 | $59 |
| Mallinckrodt Enterprises LLC | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Shire North American Group Inc | 2 | $32 |
| Bluewind Medical | 1 | $31 |
| Organon | 1 | $29 |
| Boehringer Ingelheim | 1 | $28 |
| Pacira Pharmaceuticals Incorporated | 1 | $25 |
| Johnson & Johnson | 1 | $25 |
| Urovant Sciences Inc | 1 | $24 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,808 in reported general payments places this provider in the 65th percentile of 33 urology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 67 | $61,836 |
| GemtesaVibegron | 13 | $11,520 |
| Tamsulosin Hcl | 508 | $5,961 |
| Finasteride | 312 | $4,888 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 17 | $3,167 |
| Oxybutynin Chloride ErOxybutynin Chloride | 126 | $2,792 |
| Silodosin | 29 | $2,586 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 82 | $2,475 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 26 | $1,183 |
| Ciprofloxacin Hcl | 80 | $345 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 19 | $309 |
| Sildenafil Citrate | 19 | $142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $184 | $61,83667 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $167 | $11,52013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 33 urology providers in Delaware.
Other urology in Seaford
- Elizabeth Kornfield ChadwellSeaford$4K
- Christopher MitchellWilmington$19K
- Michael LobisWilmington$8K
- Joohyong KimDover$7K
- Thomas DesperitoWilmington$7K
- Raymond BolognaMilford$7K
- Christopher VallorosiDover$7K
- Michael ZaragozaDover$6K
- Gregory SpanaDover$5K
- Bruce BengeWilmington$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.